Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Cinder Invest in connection with an investment in JumpYard
Mandate

Vinge advises Cinder Invest in connection with an investment in JumpYard

March 19, 2021 M&A

Vinge is advising Cinder Invest in connection with their investment in JumpYard. JumpYard is one of Sweden's largest operators of trampoline and activity centres and currently operates 7 trampoline parks in Sweden and another park in Denmark. The investment provides JumpYard with financial resources and expertise which enable the company to accelerate growth.

Cinder Invest is a joint venture between AFA, AMF, FAM together with the Wallenberg Foundations, the Fourth Swedish National Pension Fund and SEB. Cinder Invest will invest in viable Swedish companies in order to help them overcome the adverse economic consequences of Covid-19.

Vinge's team primarily consisted of, among others, Johan Larsson, Viktor Lennartsson, Frida Ställborn and Emil Lindwall.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024